N Lynn Henry1, Joseph M Unger2,3, Cathee Till2,3, Anne F Schott4, Katherine D Crew5, Danika L Lew2,3, Michael J Fisch6, Carol M Moinpour7, James L Wade8, Dawn L Hershman5. 1. Department of Internal Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah. 2. SWOG Statistics and Data Management Center, Seattle, Washington. 3. Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington. 4. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 5. Department of Medicine, Columbia University, New York, New York. 6. AIM Specialty Health, Chicago, Illinois. 7. Cancer Prevention Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 8. Heartland National Cancer Institute Community Oncology Research Program, Decatur, Illinois.
Abstract
BACKGROUND:Aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) negatively impact adherence to and persistence with therapy. In SWOG S1202, patients with AIMSS who were treated with duloxetine, a serotonin norepinephrine reuptake inhibitor, reported improvement in pain by 12 weeks compared with placebo. Based on the authors' prior observation that responses to pain interventions differ between obese and nonobese patients, the current study examined whether response to duloxetine therapy differed by obesity status. METHODS: In SWOG S1202, a total of 299 AI-treated postmenopausal women with stage I to III (AJCC 7th Edition) breast cancer who developed new or worsening average pain were enrolled, randomized to duloxetine or placebo, and treated for 12 weeks. Patient-reported outcomes were obtained at baseline and through 12 weeks. Patients were categorized into nonobese (body mass index [BMI] <30 kg/m2 ) or obese (BMI ≥30 kg/m2 ). The authors tested the interaction between intervention and obesity with respect to average pain at 12 weeks in the 289 eligible patients, using a P value of .05 to indicate statistical significance. RESULTS: In approximately 54% of evaluable patients with a BMI ≥30 kg/m2 , the reduction in the mean average pain score between baseline and 12 weeks was statistically significantly greater for patients treated with duloxetine compared with those receiving placebo (-2.73 vs -1.64 points; P = .003). Conversely, in the nonobese patients, the reduction in the mean average pain score was similar in the 2 cohorts (-2.46 vs -2.34 points; P = .75). The P value for interaction was .02, thereby meeting the threshold criteria of the current study. Similar findings were evident for other pain-related patient-reported outcomes. CONCLUSIONS: In this trial, obese patients with AIMSS obtained more analgesic benefit from duloxetine compared with nonobese patients. Additional studies are warranted to determine the biologic basis for these findings.
RCT Entities:
BACKGROUND: Aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) negatively impact adherence to and persistence with therapy. In SWOG S1202, patients with AIMSS who were treated with duloxetine, a serotoninnorepinephrine reuptake inhibitor, reported improvement in pain by 12 weeks compared with placebo. Based on the authors' prior observation that responses to pain interventions differ between obese and nonobese patients, the current study examined whether response to duloxetine therapy differed by obesity status. METHODS: In SWOG S1202, a total of 299 AI-treated postmenopausal women with stage I to III (AJCC 7th Edition) breast cancer who developed new or worsening average pain were enrolled, randomized to duloxetine or placebo, and treated for 12 weeks. Patient-reported outcomes were obtained at baseline and through 12 weeks. Patients were categorized into nonobese (body mass index [BMI] <30 kg/m2 ) or obese (BMI ≥30 kg/m2 ). The authors tested the interaction between intervention and obesity with respect to average pain at 12 weeks in the 289 eligible patients, using a P value of .05 to indicate statistical significance. RESULTS: In approximately 54% of evaluable patients with a BMI ≥30 kg/m2 , the reduction in the mean average pain score between baseline and 12 weeks was statistically significantly greater for patients treated with duloxetine compared with those receiving placebo (-2.73 vs -1.64 points; P = .003). Conversely, in the nonobese patients, the reduction in the mean average pain score was similar in the 2 cohorts (-2.46 vs -2.34 points; P = .75). The P value for interaction was .02, thereby meeting the threshold criteria of the current study. Similar findings were evident for other pain-related patient-reported outcomes. CONCLUSIONS: In this trial, obesepatients with AIMSS obtained more analgesic benefit from duloxetine compared with nonobese patients. Additional studies are warranted to determine the biologic basis for these findings.
Authors: Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: N J Talley; G R Locke; B D Lahr; A R Zinsmeister; M Cohard-Radice; T V D'Elia; J Tack; D L Earnest Journal: Aliment Pharmacol Ther Date: 2006-04-01 Impact factor: 8.171
Authors: Ivana Sestak; Jack Cuzick; Francisco Sapunar; Richard Eastell; John F Forbes; Angelo R Bianco; Aman U Buzdar Journal: Lancet Oncol Date: 2008-08-12 Impact factor: 41.316
Authors: Kate E Roberts; India T Adsett; Kirsty Rickett; Sophie M Conroy; Mark D Chatfield; Natasha E Woodward Journal: Cochrane Database Syst Rev Date: 2022-01-10
Authors: Tara Hyder; Christopher C Marino; Sasha Ahmad; Azadeh Nasrazadani; Adam M Brufsky Journal: Front Endocrinol (Lausanne) Date: 2021-07-27 Impact factor: 5.555